Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamaophthalmol.2015.5679 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chronic spontaneous urticaria remission definition and therapy stepping-down. WAO Position Paper.
J Allergy Clin Immunol
December 2024
Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, University of Cincinnati, USA.
Background: There is no global agreement on the definition of Chronic Spontaneous Urticaria (CSU) remission.
Objective: To generate a consensus for clinical definitions in CSU focused on remission.
Methods: The World Allergy Organization (WAO) Urticaria Committee systematically reviewed current available longitudinal articles.
Two-year follow-up after drug desensitization in mucopolysaccharidosis.
Orphanet J Rare Dis
December 2024
Post Graduate School in Allergology and Internal Medicine "Guido Baccelli", Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, Aldo Moro University of Bari, Bari, 70124, Italy.
Background: Mucopolysaccharidosis (MPS) type 1 S and type 2 are rare lysosomal storage disorders characterized by impaired enzyme production, resulting in glycosaminoglycans accumulation within lysosomes. Enzyme Replacement Therapy (ERT) with laronidase and idursulfase are first line treatments, respectively. However, infusion-related hypersensitivity reactions (HR) may lead to ERT discontinuation.
View Article and Find Full Text PDFIntroduction: Emerging evidences have underscored the positive impact of biologics on asthmatic patients. However, there is a pressing need to verify their therapeutic efficacy in children and adolescents with asthma. To address this, we conducted a network meta-analysis (NMA) to evaluate the efficacy and safety of biologics in the asthma management of this demographic.
View Article and Find Full Text PDFTreatment of food allergy: Immunotherapy, omalizumab, or both.
J Allergy Clin Immunol Pract
December 2024
Department of Pathology, Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA. Electronic address:
Food allergy is a common disease which has substantial impacts on the quality of life of patients and their families, and all reactions have the potential for causing life-threatening anaphylaxis. Food allergic individuals currently have 2 FDA approved therapeutic options available to them aside from life-long allergen avoidance: oral immunotherapy (OIT), and omalizumab. OIT for food allergy has been extensively studied in clinical trials and currently provides the greatest level of protection, however it also has a high burden of treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!